Session Abstract – PMWC 2022 Silicon Valley

The PMWC 2022 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.

- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy

Confirmed Presenting Companies:

 Session Chair Profile

M.D., Ph.D, Director (BoD), SITC

Daniel S. Chen, MD, PhD, is a Director on the Society for ImmunoTherapy of Cancer (SITC) Board of Directors, the former Chief Medical Officer for IGM Biosciences, and former Vice President, Global Head of Cancer Immunotherapy Development at Genentech/Roche. He is a reviewer for Nature, Immunity and Clinical Cancer Research, serves on the Board of Directors for SITC, gave the keynote presentation at the AACR NCI EORTC Annual Meeting 2014 and presented at the US Congressional Briefing on Immuno Oncology in 2017. He has continued to publish with academic and industry collaborators in the field of cancer immunotherapy, including the often-referenced Chen and Mellman manuscripts, “Oncology meets Immunology: the Cancer-Immunity Cycle,” “Elements of cancer immunity and the cancer-immune set point” and the Hegde and Chen manuscript “Top 10 Challenges in Cancer Immunotherapy.”

 Speaker Profile

Ph.D., Head of BD & Strategy, Novome Biotechnologies

Lane is Head of Strategy and Business Development at Novome Biotechnologies, which has developed the first platform for controllably colonizing the gut with genetically engineered cells, where he led negotiations for a recent R&D collaboration with Genentech in IBD and an asset purchase from Caribou Biosciences. Prior to Novome, Lane was a commercial strategy BD lead at Genentech (responsible for Immunology, Ophthalmology, Respiratory, and Neuroscience disease areas), where he led commercial diligence on Roche’s acquisition of Promedior. He additionally provided strategic guidance to marketed Genentech brands and was a Pipeline & Portfolio Planning Lead for Tecentriq across lung, head, & neck cancers. Before Genentech, Lane was a management consultant at L.E.K., with engagements across the life sciences sector- including in therapeutics, diagnostics, medical devices, payers, and providers. He holds a PhD in Bioengineering with a Synthetic Biology focus from the Joint Graduate Group at UC Berkeley / UCSF.

Emerging Therapeutics Showcase:
Novome Biotechnologies

Novome engineers living medicines for chronic diseases, having developed the first platform for controllably colonizing the gut with genetically engineered cells.

Engineering Living Medicines for Chronic Diseases
In this talk, we discuss Novome’s novel foundational technology for controllably colonizing the gut with therapeutically engineered cells, our broad pipeline, and clinical results from a Phase 1 study of our lead program in enteric hyperoxaluria.

 Speaker Profile

M.D., Medical Director Thoracic Onoclogy, Sutter Health

Dr. Behl specializes in lung cancer, melanoma and head and neck cancers. Dr. Behl leads clinical research and has coauthored peer-reviewed articles and published in high-impact journals such as the Journal of Clinical Oncology (JCO) and Chest.

Emerging Therapeutics Showcase:
Sutter Health

Not Just Any EGFR Mutation: The Importance of Testing for Exon 20
Patients with metastatic NSCLC with EGFR exon 20 insertion mutations have poorer outcomes than those patients who have more common EGFR mutations. Because >100 different EGFR exon 20 insertion mutations have been identified, comprehensive biomarker testing by NGS is recommended

 Speaker Profile

CEO, OneFul Health Inc

Edison Hudson is a recognized pioneer in robotics and intelligent process automation. At Panacea BioMatx Inc, he has led the design of disruptive robotic platforms for personalized medicine and clinical nutrition driven by digital health data. He has been a key innovator in several technology companies, including iRobot, Adept Technology, Unimation, Redzone Robotics, and Meta Machines, and spent over a decade working in Silicon Valley automating semiconductor and electronics manufacturing processes. Founder of 4 companies, he holds over 25 patents in automation, machine intelligence, and automated pharmacy. A Morehead Scholar at the University of North Carolina, he studied artificial intelligence at Oxford University UK, and received an MBA from Duke University.

Wellness & Aging Showcase:
OneFul Health Inc

OneFul seeks to improve the quality of life for millions of patients with affordable personalized medicine that are easier to take. Science-based formulations, made with robotic accuracy, deliver multiple drugs combined for One Person, as prescribed by One Doctor from our accredited OneFul Pharmacies.

Personalized Cardiovascular Therapies - Genomics Meets Robotics
Fixed combination cardiovascular poly-pills have been shown to greatly improve adherence in multiple clinical studies. OneFul shows how pharmacogenomic-based formulation driving highly accurate robotics can make personalized CVD poly-therapies that are more efficacious with fewer adverse effects, further enhancing poly pharmacy adherence.

 Speaker Profile

Senior Scientist, Immunology Unit, Ardigen

Giovanni Mazzocco has 10+ years of experience in academic and commercial bioinformatics projects, including collaborations with scientific institutes (e.g.Università di Padova,Interdisciplinary Centre for Mathematical and Computational Modelling, Centre of New Technologies,Krakow University, Institute of Computer Science at the Polish Academy of Sciences, Jackson Laboratory) medical research institutions, and Pharma/Biotech companies. He conducted research in computational biology including enzyme discovery, molecular modeling, dynamics and interaction assessment of proteins, chromatin modeling, design of statistical learning methods for the prediction of protein interactions of pivotal immunological significance, and design of vaccine constructs to be tested in industrial settings. Giovanni joined Ardigen to pursue the advancement of precision medicine in oncology with the application of AI. Gio is the proponent of the TCRact project, which obtained financing by the Polish Centre for Research and Development and is currently under development in the Ardigen immunology team(, NCT04994093). His role is to propose and explore scientific directions in the R&Dteam.

Emerging Therapeutics Showcase:

Ardigen is harnessing advanced AI methods for novel precision medicine. The company’s in-house datasets, together with advanced AI platforms, empower the development of effective therapies.

AI-aided Rational Design of Cancer Cell Therapies
Predicting the interaction of a TCR to target and off-target antigens can support the development of adoptive cell therapies. We will discuss how AI-assisted methods can help by incorporating sequence-level information and general patterns of interactions at the peptide, HLA, and TCR level.

 Speaker Profile

M.D., Executive Medical Director, Quest Diagnostics

Yuri Fesko, M.D., is Cheif Medical Office of Oncology at Quest Diagnostics. As a leading oncologist, Dr Fesko plays a key role in helping Quest advance the field of precision medicine and give new hope to people with cancer. Prior to joining Quest in 2017, Dr Fesko was Director of Medical Oncology at the Duke Cancer Institute in Raleigh, North Carolina, where he was responsible for the oncology service line and development of inpatient oncology, multiple network sites and infusion centers. He also was responsible for strategies including the determination of appropriate clinical trials for population and resource utilization. Dr Fesko received his bachelor’s degree and medical degree from Case Western Reserve University School of Medicine. He is certified by the American Board of Internal Medicine in hematology and medical oncology.

Emerging Therapeutics Showcase:
Quest Diagnostics

Quest Diagnostics is the Largest Reference laboratory with products and services that benefit patients, health care providers, Pharmaceutical companies , Life insurance companies and employers. Quest Diagnostics empowers people to take action to improve health outcomes.

 Speaker Profile

M.D., Ph.D., CEO and President, 3T Biosciences

Executive level leadership with extensive experience in drug development, clinical science, translational medicine and overseeing development strategies for early to late stage assets. Initiation and execution on Academic Alliances and Partnerships. Known for versatility and unique ability to extend skills across diverse functional roles, including strategic planning, product development, brand strategies, ability to develop trusted relationships with both internal and external partners, exceptional medical and scientific knowledge with a broad understanding of disease entities and corresponding molecular and business implications.